Serum Lipase Levels Carry Prognostic Value in Small Bowel Obstruction
Rattachement africain : us. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Introduction: In small bowel obstruction (SBO), there is an interruption in the passage of intestinal contents through the gut lumen. Case reports have described elevated pancreatic enzymes in patients with small bowel obstruction initially misdiagnosed as having pancreatitis. To our knowledge, there is no study which systematically addresses the issue or the prognostic value of elevated serum lipase in SBO.Table: Table. Patients' Baseline Characteristics (n=344)Methods: Patients with SBO and at least one serum lipase level identified between September 2013 and September 2016 were evaluated. Demographic, laboratory and imaging information; need for surgery or intensive care unit and mortality were evaluated. Results: Of 344 patients, 38 (11%) had elevated serum lipase levels. Patients with radiographic diagnosis of pancreatitis were excluded. Patients with elevated lipase had significantly higher levels of creatinine and lactic acid levels, length of stay, need for intensive care monitoring and death than patients with normal lipase levels. The need for surgical intervention was not significantly different between the two groups.Table: Table. Comparison of Patients with SBO and Normal or Elevated Serum LipaseConclusion: Small bowel obstruction should be considered in the differential diagnosis for elevated serum lipase levels. Abdominal computed tomography constitutes a useful resource to differentiate SBO from acute pancreatitis. In SBO, elevated serum lipase is a risk factor for higher serum creatinine and lactate, use of ICU, and mortality.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Serum Lipase Levels Carry Prognostic Value in Small Bowel Obstruction
- Date Crossref
- 01/10/2017
- Éditeur
- Ovid Technologies (Wolters Kluwer Health)
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
The University of Texas Health Science Center at Houston pays non établi dans la noticeUniversité ou école supérieure
The University of Texas Health Science Center at Houston.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.